Moleculin Biotech CEO Walter Klemp receives 577 shares as restricted stock units vest
MBRX•Moleculin Biotech CEO and President Walter V. Klemp acquired 577 common shares through restricted stock unit conversion on Nov. 16, 2026. After the transactions, he directly held 36,545 common shares and 126,838 restricted stock units.




